Ignite Proteomics offers the only commercially available and clinically validated assay that measures both the expression and activation levels of drug targets in breast tumors. This innovative ...

Ignite Proteomics announces the publication of a significant study in the British Journal of Cancer titled “Functional activation of the ...

Mutations in PIK3CA, AKT1, and alterations in PTEN occur frequently ... of Truqap “reinforces the important role of the PI3K/AKT pathway in HR-positive breast cancer and the critical need ...

and PTEN-mutated breast cancer. So far, no AKT inhibitors have been brought to market, but several remain in clinical development. Roche's decision to drop the programme comes after AstraZeneca's ...